Abaxis Inc

Abaxis — Merger or Acquisition (May 2018)

16 slides from Abaxis's merger presentation, May 16, 2018

  1. Slide 1: Introducing You to Zoetis

    INTRODUCING YOU TO ZOETIS May 16, 2018

  2. Slide 2: Forward-Looking Statements

    FORWARD-LOOKING STATEMENTS Statements included in this communication which are not historical in nature or do not relate to current facts are intended to be, and are hereby identified as, forward-looking statements for purposes of the safe harbor provided by Section 27A of the Securities Act of 1933

  3. Slide 3: Important Additional Information

    IMPORTANT ADDITIONAL INFORMATION In connection with the proposed transaction between Zoetis and Abaxis, Abaxis expects to file with the SEC a proxy statement of Abaxis, as well as other relevant documents concerning the proposed transaction. This communication is not a substitute for the proxy state

  4. Slide 4: Zoetis discovers, develops, manufactures and markets veterinary vaccines and medicines

    Building on more than 60 years of experience, Zoetis discovers, develops, manufactures and markets veterinary vaccines and medicines, complemented by diagnostic products, genetic tests, biodevices and a range of services.

  5. Slide 5: Our Vision and Our Mission

    OUR VISION OUR VISION GUIDES OUR ASPIRATIONS Our products, services and people will be the most valued by animal health customers around the world. OUR MISSION OUR MISSION GUIDES OUR ACTIONS We build on a six-decade history and singular focus on animal health to bring customers quality products, ser

  6. Slide 6: Zoetis at a Glance

    MANUFACTURING ANIMAL CORE SITES $ 25 8 SPECIES 5.3 APPROXIMATE APPROXIMATE COLLEAGUES R&D NUMBER OF BILLION 300 PRODUCT LINES ANNUAL REVENUE 1,000 WE PROVIDE VACCINES MEDICINES DIAGNOSTICS MAJOR PRODUCT GENETIC TESTS YEARS OF CATEGORIES BIODEVICES 5 SERVICES 60+ EXPERIENCE MARKET PRESENCE IN APPROXI

  7. Slide 7: Addressing Customer Needs: The Zoetis Advantage

    ADDRESSING CUSTOMER NEEDS THE ZOETIS ADVANTAGE • Global Leadership and Scale • Diverse Portfolio • Interconnected Capabilities: • Direct Customer Relationships • Innovation • High Quality Manufacturing • Singular Focus

  8. Slide 8: Zoetis Leads Animal Health Industry

    ZOETIS LEADS ANIMAL HEALTH INDUSTRY 2017 AH REPORTED SALES (INCLUDING NON-AH SALES1) 6,000 5.3Bn Since 2013, AH industry Mn) 5,000 has grown avg. of 5-6% — 4.4Bn with Zoetis growing in line 3.9Bn (US$ 4,000 with or faster than the sales 3.1Bn market — an average of 7% 3,000 5,307 for same period. 44

  9. Slide 9: Innovating Across the Continuum of Care

    INNOVATING ACROSS THE CONTINUUM OF CARE PREDICT PREVENT DETECT TREAT DATA VACCINES, DIAGNOSTICS MEDICINES GENETICS ANALYTICS ROBOTICS & & SENSORS AUTOMATION INTERNAL CAPABILITIES COMPLEMENTED WITH EXTERNAL PARTNERSHIPS

  10. Slide 10: Experienced Management Team

    EXPERIENCED MANAGEMENT TEAM It is our vision to have the products, services — and people — most valued by animal health customers around the world. We are proud to be led by some of the most passionate, experienced experts in the industry. JUAN RAMÓN ALAIX Chief Executive Officer HEIDI CHEN Executiv

  11. Slide 11: Our Culture

    OUR CULTURE OUR CORE BELIEFS FORM THE FOUNDATION OF OUR CULTURE AWARD-WINNING WORKPLACE

  12. Slide 12: Accelerating Growth Together

    ACCELERATING GROWTH TOGETHER

  13. Slide 13: Next Steps

    NEXT STEPS Today -Announcement • Definitive agreement signed • Each company continues to do business as usual • Important elements remain the same: your current work, compensation & benefits continue Integration Planning • Details about future integrated company begin to be determined Close – Before

  14. Slide 14: On Your Mind

    ON YOUR MIND Future Compensation, Business Benefits, Employment Structure & Policies With Zoetis Leadership

  15. Slide 15: Questions?

    QUESTIONS?

  16. Slide 16: www.zoetis.com

    www.zoetis.com zoetis.com

Abaxis — Merger or Acquisition (May 2018) on 6ix